Adicet Bio, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Adicet Bio, Inc. (ACET) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value of $92.52 million as of 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Notes › Investments › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate · last filed 2018-11-13
- 2018-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $92.52M.
- 2018-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $74.57M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2018-09-30 | $92.52M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $74.57M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |